- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02481440
Repeated Subarachnoid Administrations of hUC-MSCs in Treating SCI
Repeated Subarachnoid Administrations of Human Umbilical Cord Mesenchymal Stem Cells in Treating Spinal Cord Injury
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Spinal cord injury (SCI) is a devastating disease and often leads to lifelong disability, muscle spasm, sensory deficits, autonomic disturbances, as well as bowel and bladder incontinence, all of which can cause tremendous troubles to patients but are lack of any effective treatment up to now. SCI is not only a severe healthy problem but also a great social burden. To the best of our knowledge, cell therapy seems to be a promising alternative for the treatment of SCI due to numerous advantages. However, cytotherapy is still in its infancy since there are many disparities and uncertainties regarding subject selection, cellular type, transplantation timing, administration dose and deliver route in clinical trial protocols. Hence, a standardized well-designed clinical study is urgently required for the safe and effective treatment of SCI.
In this study, complete or incomplete cervical, thoracic, and thoracolumbar SCI subjects were recruited to join in a prospective, single-center, single-arm clinical trial. Intervention is four times of subarachnoid administration of allogeneic hUC-MSCs. During the intervention and follow-up periods of this trial, any adverse event was identified rapidly and managed properly. The maximum intensity and relationship of any adverse event with hUC-MSCs administration were identified.The primary efficacy indicator is American spinal injury association (ASIA) total score at the fourth follow-up and SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) total score at the fourth follow-up. Secondary efficacy indicators are these two indicators at the remaining time points, scores of pin prick, light touch, motor and sphincter, muscle spasticity and spasm, autonomic system, bladder and bowel functions, residual urine volume. Subgroup analysis of primary efficacy indicators was also performed.
In this trial, informed consent forms that had the approval of the institutional review board were obtained from all participants before recruitment. In this clinical study, subarachnoid transplantation of hUC-MSCs was performed a total of four times per subject with the delivery dose of 1×10E6 cells/kg. After the completion of cytotherapy, subject was regularly followed up in the hospital at four time points, determined at 1, 3, 6, and 12 months following the final administration of hUC-MSCs. At each time point of administration (the first, second, third, and fourth transplantation) and follow-up (the first, second, third, and fourth follow-up), safety and efficacy indicators were collected accordingly by two independent assessors.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510630
- The Third Affiliated Hospital of Sun Yat-sen University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- complete or incomplete trauma-induced SCI [American Spinal Injury Association (ASIA) Impairment Scale classification: A-D] that happened at least two months before recruitment;
- aged between 18 and 65 years;
- agreed to participate in this study voluntarily and be regularly followed up for 12 months after the completion of hUC-MSCs administration
Exclusion Criteria:
- ankylosing spondylitis, myelitis, or vascular abnormalities within the spinal cord parenchyma;
- severe comorbidities, including but not limited to craniocerebral injury, cutaneous back infection, psychiatric disease, or cancer;
- pregnancy or lactation (for females);
- predicted lifespan of less than 12 months following the end of hUC-MSCs transplantation;
- participation in any other stem cell-related clinical trials that might affect accurate neurological evaluations in the present trial;
- any medical condition that, in the opinion of investigators, may pose a safety risk to any subject in this study, confound safety or efficacy assessments, or interfere with study participation
Rejection Criteria:
- misdiagnosis;
- use of any medication that may significantly impact the assessment accuracy of stem cell engraftment;
- absence of any evaluation outcome at any time point during the follow-up period
Cessation Criteria:
- individual wishes of the subjects;
- occurrence of any stem cell-associated serious adverse event (SAE) that may aggravate neurological dysfunction, or require prolongation of existing hospitalization, or need hospital readmission, or impair consciousness, or be life-threatening, or even lead to death in any subject;
- detection of any major mistake in the present protocol during the implementation of this clinical trial;
- the national administration agency requires the clinical trial to be halted
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: hUC-MSC Transplantation
Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration
|
Four times of intrathecal administrations of hUC-MSCs
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
American Spinal Injury Association (ASIA) Total Score at the Fourth Follow-up
Time Frame: at 12 months following the final administration of hUC-MSCs
|
American Spinal Injury Association (ASIA) form is used to assess ASIA total score (Range: 0-324 scores).
The higher scores mean a better outcome.
|
at 12 months following the final administration of hUC-MSCs
|
SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score at the Fourth Follow-up
Time Frame: at 12 months following the final administration of hUC-MSCs
|
SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) form is used to assess IANR-SCIFRS total score (Range: 0-51 scores).
The higher scores mean a better outcome.
|
at 12 months following the final administration of hUC-MSCs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
American Spinal Injury Association (ASIA) Total Score
Time Frame: at first, second, third, and fourth transplantation and 1, 3, 6 months following the final administration of hUC-MSCs
|
American Spinal Injury Association (ASIA) form is used to assess ASIA total score (Range: 0-324 scores).
The higher scores mean a better outcome.
|
at first, second, third, and fourth transplantation and 1, 3, 6 months following the final administration of hUC-MSCs
|
SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score
Time Frame: at first, second, third, and fourth transplantation and 1, 3, 6 months following the final administration of hUC-MSCs
|
SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) form is used to assess IANR-SCIFRS total score (Range: 0-51 scores).
The higher scores mean a better outcome.
|
at first, second, third, and fourth transplantation and 1, 3, 6 months following the final administration of hUC-MSCs
|
International Standards to Document Remaining Autonomic Function After Spinal Cord Injury (ISAFSCI) Score
Time Frame: at first transplantation and 12 months following the final administration of hUC-MSCs
|
International Standards to document remaining Autonomic Function after Spinal Cord Injury (ISAFSCI) form is used to assess ISAFSCI score (autonomic nervous function) (Range: 5-32 scores).
The higher scores mean a better outcome.
|
at first transplantation and 12 months following the final administration of hUC-MSCs
|
Penn Scale
Time Frame: at first transplantation and 12 months following the final administration of hUC-MSCs
|
Penn scale form is used to assess muscle spasm (Range: 0-4 scores).
The higher scores mean a worse outcome.
|
at first transplantation and 12 months following the final administration of hUC-MSCs
|
Modified Ashworth Scale
Time Frame: at first transplantation and 1, 3, 12 months following the final administration of hUC-MSCs
|
Modified Ashworth scale form is used to assess muscle spasticity (Range: 0-16 scores).
The higher scores mean a worse outcome.
|
at first transplantation and 1, 3, 12 months following the final administration of hUC-MSCs
|
Geffner Scale
Time Frame: at first transplantation and 12 months following the final administration of hUC-MSCs
|
Geffner scale form is used to assess bladder function (Range: 0-7 scores).
The higher scores mean a better outcome.
|
at first transplantation and 12 months following the final administration of hUC-MSCs
|
Neurogenic Bowel Dysfunction (NBD) Scale
Time Frame: at first transplantation and 12 months following the final administration of hUC-MSCs
|
Neurogenic Bowel Dysfunction (NBD) scale form is used to assess bowel function (Range: 0-47 scores).
The higher scores mean a worse outcome.
|
at first transplantation and 12 months following the final administration of hUC-MSCs
|
Residual Urine Volume
Time Frame: at first transplantation and 12 months following the final administration of hUC-MSCs
|
Ultrasonic examination is used to assess residual urine volume
|
at first transplantation and 12 months following the final administration of hUC-MSCs
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Min Li Rong, M.D., Third Affiliated Hospital, Sun Yat-Sen University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- hUC-MSC-SCI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injuries
-
Khon Kaen UniversityUnknownInjuries, Spinal Cord
-
Universidade do Vale do ParaíbaCompletedInjuries, Spinal Cord
-
InVivo TherapeuticsTerminated
-
Ekso BionicsBurke Medical Research InstituteCompletedInjuries, Spinal CordUnited States
-
ReWalk Robotics, Inc.Unknown
-
Shepherd Center, Atlanta GACompletedInjuries, Spinal Cord
-
Wroclaw Medical UniversityInstitute of Immunology and Experimental Therapy of the Polish Academy of... and other collaboratorsUnknownComplete Spinal Cord InjuriesPoland
-
University of MiamiViewray Inc.Not yet recruitingSpinal Cord Compression | Metastatic Epidural Spinal Cord CompressionUnited States
Clinical Trials on human umbilical cord mesenchymal stem cells (hUC-MSCs)
-
Shanghai East HospitalCompleted
-
Institute of Hematology & Blood Diseases HospitalActive, not recruitingThrombocytopenia | Mesenchymal Stem CellsChina
-
Cytopeutics Sdn. Bhd.Universiti Kebangsaan Malaysia Medical CentreCompleted
-
Hai LiNot yet recruiting
-
Shenzhen Hornetcorn Bio-technology Company, LTDThe Fifth Affiliated Hospital of Guangzhou Medical UniversityCompletedOsteoarthritis | Cartilage DiseasesChina
-
Shenzhen Hornetcorn Bio-technology Company, LTDThe Second Affiliated Hospital of University of South ChinaUnknown
-
Shenzhen Hornetcorn Bio-technology Company, LTDThe Second Affiliated Hospital of University of South ChinaUnknown
-
CryoCord Sdn BhdUniversity of MalayaRecruitingFistula in Ano | Perianal Fistula Due to Crohn's DiseaseMalaysia
-
Shenzhen Beike Bio-Technology Co., Ltd.The Second Affiliated Hospital of Kunming Medical UniversityUnknown
-
Affiliated Hospital to Academy of Military Medical...Unknown